Recent Updates
Recently added Catalysts
IMCC Positive Sentiment

IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

Key Takeaway: IM Cannabis Corp. (NASDAQ: IMCC) announced that it will report its financial results for the second quarter of 2025 on August 12, 2025, prior to market opening. The company continues to operate in the medical cannabis sectors of Israel and Germany, focusing on premium cannabis products. IMC aims for sustainable growth while maintaining compliance with regulatory standards and harnessing a unique global supply chain.
Price reaction · baseline $2.53 (2025-08-01 close) · clean, no other IMCC news in the window
day 0 close · peak
+4%

Market Sentiment Analysis

POSITIVE FACTORS

  • IM Cannabis is set to report financial results, indicating ongoing operations and potential growth.
  • The company is focused on sustainable and profitable growth in key markets, Israel and Germany.
  • IMC leverages a data-driven approach and strong regulatory compliance to enhance its market position.

Full Press Release Details

TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Anna Taranko, Director Investor & Public Relations

Frequently Asked Questions

When will IM Cannabis report its Q2 2025 financial results?

IM Cannabis will report its Q2 2025 results on August 12, 2025, before market opening.

Which markets does IM Cannabis operate in?

IM Cannabis operates in Israel and Germany, focusing on the medical cannabis sector.

What is IM Cannabis's growth strategy?

IM Cannabis aims for sustainable growth in high-value markets like Israel and Germany.

How does IM Cannabis ensure product delivery?

IM Cannabis utilizes pharmacies, online platforms, and distribution centers for safe deliveries.

Who oversees investor relations at IM Cannabis?

Anna Taranko is the Director of Investor & Public Relations at IM Cannabis.

Last updated: Aug 4, 2025